Money-saving Meds: Researchers Use Pharmaceutical Risk Assessment to Determine New Drug’s Cost-Cutting Benefits

In the April issue of the International Journal of Nephrology and Renovascular Disease, researchers from  the DaVita Clinical Research in Minneapolis, MN used Palisade's @RISK software to develop a cost-offset model that cuts costs for end-stage renal disease treatment using an innovative pharmacological treatment.   Currently, about 400,000 end-stage renal disease (ESRD) patients in the US […]